AI주식인사이트AI Stock Insight
C

툴젠

199800KOSDAQ자연과학 및 공학 연구개발업

48.3 / 100

Reference Date: 2026-06-10

Financial Score16.5 / 40
News Sentiment16.8 / 25
Momentum3.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 62.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Toolgen specializes in gene-editing R&D, patent monetization, and the development of therapeutics and functional seeds using CRISPR/Cas9 and other technologies. As the world's only company to develop three types of gene-editing tools (ZFN, TALEN, CRISPR/Cas9), it leads in therapeutic drug development (e.g., TGT-001, TG-wAMD) and functional crop seed innovation (e.g., high-oleic soybeans, disease-resistant potatoes).

Number of Employees

66people

Average Salary

72.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 62.704.0Point
PBR
7.15Industry Average 3.240.0Point

2.2x industry avg (risky)

ROE
-64.34Industry Average -32.093.5Point

2.0x industry avg (excellent)

Debt Ratio
2.89Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼17.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -44.8% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 2Neutral 2Negative 1Average Sentiment Score 67

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 44,400Won52-week high 138,20052-week low 27,000
1-month return0.0Point

1m -62.53% (strong drop)

Volume trend2.0Point

Volume flat

Detailed Disclosure

3 totalPositive 1Neutral 2Negative 0
  • Positive주요사항보고서(유상증자결정)2026-05-15
  • Neutral증권신고서(지분증권)2026-05-15
  • Neutral분기보고서 (2026.03)2026-05-14